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INTRODUCTION
Colorectal signet-ring cell carcinoma (SRCC) is a rare his-
tological type of tumor reported to be 0.7-2.4% of all prima-
ry colorectal carcinomas (1-3). It is a mucin-secreting ade-
nocarcinoma with abundant intracytoplasmic mucin and
deviated nuclei. Primary colorectal SRCC consists of signet-
ring cells comprising more than half of the entire number
of tumor cells. It is also necessary that all other primary can-
cers, especially gastric cancer, must be excluded (1, 2). Colo-
rectal SRCC is assumed to present distinctive features in
contrast to ordinary colorectal adenocarcinoma, i.e. aggres-
sive infiltration to surrounding tissues, frequent peritoneal
seeding, and poor prognosis (1-3). In one investigation, the
two categories of colorectal adenocarcinoma including SRCC
were found to differ in such molecular events as microsatel-
lite instability and K-ras mutation, without any clear expla-
nation of their divergent biological behavior (4).
E-cadherin, a cadherin family member of the cell surface
glycoprotein, is a Ca
2+- dependent cell-to-cell adhesion
molecule found mainly in epithelial tissue. It is thought to
implicate embryogenesis, cellular migration in inflammato-
ry tissue, and cellular differentiation or dedifferentiation (5).
The extracellular domain interacts homotypically with the
E-cadherin molecules of neighboring cells while maintain-
ing intercellular adhesion. Its cytoplasmic tail constitutes
complex with a group of intracytoplasmic proteins, such as
catenins (6, 7). E-cadherin and catenin unit binds to the
cytoskeleton that is essential for the adhesive function of E-
cadherin. Furthermore, E-cadherin and catenins appear to
act as more of an intercellular glue.  -catenin seems to par-
ticipate in the signal transduction from the cellular surface
to the cytoplasm independently from the cell-to-cell adhe-
sion. Catenins also correlate with molecules of growth regu-
latory and signaling functions, i.e. adenomatous polyposis
coli (APC) protein, axin, and TCF/Lef transcriptional factors
(8). APC protein plays a key role in approximately 80% of
colorectal carcinogenesis, competing directly with E-cad-
herin in binding to  -catenin; it also appears to be an indi-
rect regulator of E-cadherin-mediated adhesion (9).
Many investigators have suggested the suppressor role of
E-cadherin in tumor invasion (10). Loss or diminished expres-
sion by mutation or epigenetic change has been demonstrat-
ed in many epithelial cancers (11-13). The down-regulation
of E-cadherin is seen most prominently in carcinomas show-
ing infiltrative growth associated with little intercellular
cohesion, such as invasive lobular carcinoma of the breast
and diffuse gastric adenocarcinoma including gastric SRCC
Hee Cheol Kim, Ho Jeong Kim*,
Jin Cheon Kim
Departments of Surgery and Pathology*, University
of Ulsan College of Medicine and Asan Medical
Center, Seoul, Korea
Received : 16 August 2001
Accepted : 8 October 2001
Address for correspondence
Hee Cheol Kim, M.D.
Department of Surgery, University of Ulsan College
of Medicine and Asan Medical Center, 388-1,
Poongnap-dong, Songpa-gu, Seoul 138-736,
Korea
Tel : +82.2-3010-3937, Fax : +82.2-474-9027
E-mail : hckim@www.amc.seoul.kr
*This study was supported by the Grant of the
Asan Institute for Life Sciences (2000), Seoul,
Korea.
23
J Korean Med Sci 2002; 17: 23-8
ISSN 1011-8934
Copyright � The Korean Academy
of Medical Sciences
Reduced E-Cadherin Expression as a Cause of Distinctive
Signet-Ring Cell Variant in Colorectal Carcinoma
Colorectal signet-ring cell carcinoma (SRCC) is a rare type of adenocarcinoma
and presents with distinctive clinicopathological features. This study was per-
formed to assess the biological characteristics of colorectal SRCC regarding the
E-cadherin expression. Seventeen patients with primary colorectal SRCC were
identified and their clinicopathological characteristics were analyzed. The mean
age of the 17 patients was 45.3 yr (14-68). Immunohistochemical staining of E-
cadherin and  -catenin were performed in ten colorectal SRCCs and in 30 ordi-
nary colorectal adenocarcinomas as control. Primary colorectal SRCC occurred
in 0.7% of 2,388 colorectal adenocarcinomas. Most patients had advanced stage
tumor at surgery (stage III and IV, AJCC: 82%). Five-year survival rate was 16%.
Peritoneal seeding was the most common recurrence pattern (41%) and liver
metastasis was not identified. All SRCCs showed a markedly reduced or absent
expression of E-cadherin on immunohistochemical staining, whereas seven
(23.3%) of ordinary carcinomas showed reduced expression, thereby indicating
a significant difference between the two groups (p<0.005). In immunohistochemi-
cal staining for  -catenin, eight of ten SRCCs showed reduced membrane expres-
sion that did not attain statistical significance compared to ordinary adenocarci-
nomas. It is suggested that aberrant E-cadherin expression may explain the dis-
tinct clinicopathological features in primary colorectal SRCC.
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(14, 15). Therefore, the loss of the E-cadherin function could
be associated with invasiveness, lymph node metastasis, and
distant metastasis resulting in poor prognosis (10, 16).
Few investigations have explained the mechanism of the
distinctive phenotype and aggressive clinical behavior in
colorectal SRCC. This study assessed the correlation between
the clinicopathological features of colorectal SRCC and the
expression of E-cadherin in order to identify the biological
characteristics of E-cadherin in colorectal SRCC.
PATIENTS AND METHODS
Patients
Seventeen patients (0.7%) with primary colorectal SRCC
were included among the 2,388 patients who underwent
primary colorectal carcinoma surgery between 1989 and
1999 at the Asan Medical Center (Seoul, Korea). The clini-
copathological findings were evaluated retrospectively. All
tumors were examined in duplicate and identified as SRCC
when more than 50% of the tumor cells were signet-ring
cells. Metastatic SRCCs were excluded by operative find-
ings as well as by preoperative imaging studies and endo-
scopy. There were nine male and eight female patients.
Their mean age was 45.3 yr (range 14-68), and seven
patients (41%) were younger than 40 yr.
Thirty colorectal carcinomas with well or moderately dif-
ferentiated cell types (six well and 24 moderate differentiat-
ed cell type) were used as control group. They consecutively
underwent surgery during the year 2000. The mean age of
the control group was 56.5 yr (35-79), and there were 17
male and 13 female patients. The mean age of the control
group was significantly greater than that of the SRCC group
(p<0.05), whereas the sex ratio, tumor location, and stage
were not different between the two groups.
Immunohistochemical Staining and Interpretation
Immunohistochemical staining was available in ten SRCCs
using archival paraffin blocks. Early seven tissue blocks were
lost in flood accident of the Asan Medical Center in 1988.
Briefly, endogenous peroxidase activity was blocked by incu-
bation in 0.5% hydrogen peroxide in methanol for 15 min.
Antigen was retrieved by heating in a sodium citrate solu-
tion (0.1 M, pH 6.0) in a pressure cooker maintaining 15 psi
for 30 min. Sections were incubated for 30 min with normal
rabbit serum (Dako, Capinteria, CA) and then incubated
with a mouse monoclonal antibody for E-cadherin (Takara,
Shiga, Japan) (17) and  -catenin (Tranduction Labs., Lexing-
ton, KY) (18) overnight at room temperature. After washing
in phosphate-buffered saline (PBS), sections were incubated
with mouse and horseradish-peroxidase-labeled streptavidin,
respectively (1:200 dilution each). Diaminobenzidine hydro-
chloride (DAB) was used as the chromogen.
The percentage of cells showing positive membrane
staining for E-cadherin or  -catenin was graded as negative
for no staining, one for ≤25%, two for >25 -≤50%, three
for >50 -≤75%, and four for >75%. The staining intensi-
ty was graded according to the color guide (4th ed., Dainip-
pon Ink and Chemicals Inc., Tokyo, Japan) as negative for
no staining, weak for light brown (No. 335), moderate for
brown (No. 338), and intense for brown (No. 341) (19). A
weighted score was obtained by multiplying the percentage
by the intensity, and ranged from 0 to 12. Score 9-12 was
defined as strong staining, 5-8 as reduced staining, 1-4 as
greatly reduced staining, and 0 as negative (20, 21). Nucle-
ar staining for  -catenin was considered as positive when ≥
5% of the nuclei were stained and as negative when <5%
were stained (21).
Statistical Analysis
Comparison between the clinical factors and immunohis-
tochemical staining was performed using the chi-square
test, Fisher’ s exact test, and the Spearman correlation analy-
sis. The survival time and the cumulative survival rate were
estimated using the Kaplan-Meier method. The signifi-
cance level was set at 5% for each analysis, and the SPSS
(version 9.0, SPSS Inc) was used for statistical analysis on an
IBM PC.
RESULTS
Clinical Characteristics of Patients with Colorectal
SRCC
No patient with colorectal SRCC had a familial history of
malignant disease, including colorectal cancer and hereditary
non-polyposis colorectal cancer with its associated malignan-
cy. Synchronous colon cancer was also present in one patient.
Colorectal SRCC was evenly distributed along the entire
colon, i.e. five cases on the right colon, four on the left colon,
and eight on the rectum. The gross appearance of linitis
plastica was found in four patients (24%). Stage III occurred
most frequently (11 cases), followed by Stage IV (three cases)
(Table 1).
During a median follow-up of 18 months, nine patients
died due to recurrence in 14 patients who had not had dis-
tant metastasis on primary surgery. Peritoneal seeding was
the most frequent mode of recurrence (seven patients, 41%).
Four patients (24%) showed brain metastases and three
patients (18%) showed bone metastases; hepatic metastasis
was not identified. Two year and five-year overall survival
rates were 32% and 16%, respectively. There was no differ-
ence in any of the clinicopathologic features in all 17 SRCC
cases as well as ten cases of immunohistochemical staining.E-cadherin Expression in SRCC 25
Immunohistochemical Staining of E-cadherin and  -
catenin in Colorectal SRCC
Normal colonic epithelium showed punctuate basolateral
membrane staining for E-cadherin along the entire length
of the crypt; this served as an internal positive control. All
colorectal SRCC showed variable degrees of decreased mem-
brane expression (Table 2). It was noted that no expression
was found in four of ten cases. In 30 control cases, normal
E-cadherin expression was found in 23 cases and reduced
expression was identified in seven cases. The E-cadherin
expression of colorectal SRCC significantly differed from
that of ordinary colorectal cancers (p<0.001)
The membrane expression of  -catenin was preserved in
two cases of colorectal SRCC and 10 cases in the control
group without a significant difference between the two
groups. Nuclear expression of  -catenin was identified in
nine cases of colorectal SRCC and in 22 cases in the control
group (Table 3). All cases showing decreased membrane
expression showed nuclear expression. There was no correla-
tion between the membrane expression of E-cadherin and
that of  -catenin (Spearman correlation coefficient=-0.092).
DISCUSSION
Laufman and Saphir (1951) described colorectal SRCC as
a distinct type of primary neoplasm of the large bowel. A
substantial number of studies have reported that colorectal
SRCC presents with different biologic behavior and a differ-
ent clinical course compared to ordinary colorectal adeno-
carcinomas (1-3). Colorectal SRCC is rarely associated with
adenomatous polyps and a family history of colorectal cancer
No Sex Age (yr) Location* Gross type
� Stage
� Recurrence Survival (months)
�
1 F 14 Right colon III II Peritoneum, Brain 21
2 F 20 Left colon II IV Lymph node 53
3 M 25 Left colon IV III Peritoneum 16
4 M 29 Rectum IV III Lymph node, Bone 13
5 F 30 Rectum IV III Peritoneum, Bone 23
6 F 35 Left colon III III - 70+
7 M 38 Rectum II III Bone, Brain 8
8 M 45 Right colon III IV Peritoneum 3
9 M 53 Right colon III III Bone, Brain 15
10 M 53 Rectum III III - 28+
11 F 57 Right colon III IV Peritoneum 18
12 F 58 Right colon III II - 49+
13 M 60 Rectum I I - 13+
14 F 60 Left colon III III - 50+
15 F 61 Rectum IV III Peritoneum, Brain 14
16 M 65 Rectum III III Local 18
17 M 68 Rectum II III Peritoneum 14
Table 1. Clinicopathologic characteristics in 17 patients with colorectal signet-ring cell carcinoma
*Right colon includes the cecum, ascending colon, and transverse colon; Left colon includes descending colon and sigmoid colon. 
� Gross type I,
protruding; II, ulcerofungating; III, ulceroinfiltrative; IV, diffuse (Linitis plastica). 
� Stage according to the American Joint Committee on Cancer (AJCC,
1997). 
� ‘+’ means that patient was alive at the last follow-up.
*A weighted score was obtained by multiplying percentage by the
intensity. 
� Colorectal signet-ring cell carcinoma. Chi-square test (9-12
vs. 5-8, 1-4, and 0), p<0.005.
Weighted score*
Preserved Reduced
9-12 (%) 5-8 1-4 0 Reduced (%)
Ordinary adenocarcinoma 23 (76.7) 6 1 0 7 (23.3)
SRCC
� 0 (0) 1 5 4 10 (100)
Table 2. The membrane expression of E-cadherin in colorectal
signet-ring cell carcinomas and in ordinary adenocarcinomas
*Colorectal signet-ring cell carcinoma. 
� A weighted score was obtained
by multiplying percentage by the intensity: chi-square test (9-12 vs. 5-
8, 1-4, and 0), p=0.69. 
� Chi-square test, p=0.40.
Ordinary adenocarcinoma (%) SRCC* (%)
Membrane expression 
(Weighted score
� )
Preserved (9-12) 10 (33.3) 2 (20)
Reduced 20 (66.7) 8 (80)
5-8 12 4
1-4 8 3
00 1
Nuclear expression
�
Positive 22 (73.3) 9 (90)
Negative 8 (26.7) 1 (10)
Table 3. Membrane and nuclear expression of  -catenin in col-
orectal signet-ring cell carcinoma and in ordinary adenocarci-
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in contrast to ordinary colorectal adenocarcinoma showed a
15-20% rate of familial clustering. According to the three
recent controlled studies, the survival outcome of SRCC
was uniformly poorer than that of ordinary adenocarcino-
mas (1-3). Furthermore, the metastatic pattern of frequent
peritoneal dissemination, and the relatively rare occurrence
of liver metastasis, are the features of colorectal SRCC, which
distinguish it from ordinary colorectal adenocarcinoma. In
this study, we also identified these clinical characteristics of
colorectal SRCC. These observations might suggest a differ-
ent molecular behavior implying the characteristic carcino-
genesis and progression of colorectal SRCC.
The loss of function in any of the E-cadherin-catenin com-
plex components has been suggested as the cause of loss of
epithelial differentiation and architecture or the acquisition
of a motile and invasive phenotype (22). Alteration in the
expression or function of E-cadherin in carcinomas may allow
certain carcinoma cells to be readily detached from the sur-
rounding structure and thereby develop a more infiltrative
growth pattern. A variety of human malignancies, includ-
ing thyroid, esophagus, gastric, and colon adenocarcinomas,
have shown that reduced E-cadherin expression is correlated
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Fig. 1. A: Normal mucosa showing uniformly membranous expression of E-cadherin (×200). B: Preserved expression of E-cadherin
(Grade 3 with strong intensity in moderately differentiated adenocarcinoma, ×200). C: Reduced expression of E-cadherin (Grade 1 with
weak intensity in colorectal SRCC, ×200). D: Absent expression of E-cadherin in SRCC (×200).E-cadherin Expression in SRCC 27
with tumor dedifferentiation, infiltrative growth, and lymph
node involvement (23, 24). E-cadherin loss has frequently
been reported in gastric SRCC and lobular breast carcinoma.
Approximately half of gastric SRCCs included mutations in
the E-cadherin gene (CDH1) resulting in a low or aberrant
expression of protein. In our study, the significantly reduced
E-cadherin expression in colorectal SRCC was found and
suggest that an aggressive biological behavior of colorectal
SRCC is partly contributed by aberrant E-cadherin expres-
sion.
E-cadherin appears to be the common target for soluble
growth factors and cytokines, such as the epidermal growth
factor (EGF), the transforming growth factor  (TGF  ),
the hepatocyte growth factor/scatter factor (HGF/SF), and
the trefoil factor (25). The trefoil peptides of secreted pro-
teins found predominantly in mucus-secreting cells, have
been thought to promote migration of intestinal epithelial
cells and to enhance mucosal healing and epithelial restitu-
tion (25, 26). In colon cancer cell lines, trefoil factor has been
shown to modulate epithelial cancer cell adhesion, migration,
and apoptosis by disturbing the complexes among E-cad-
herin,  -catenin, and associated proteins (11, 27). Although
the mechanism of the trefoil factor is not precisely known,
the trefoil factors activate the EGF receptor pathway to effect
cell-to-cell adhesion (27, 28). It has been found that trefoil
factors and mucins are often coexpressed in mucous cells in
a closely related manner. Moreover, a recent study reported
that the trefoil factor participated in mucus formation and
protected the gastrointestinal mucosa via mucin binding
(29). SRCC characteristically includes abundant intracyto-
plasmic mucin. The down-regulation of E-cadherin in colo-
rectal SRCC may be associated with mucin, trefoil factors,
and other growth factors, which produce an aggressive phe-
notype of colorectal SRCC.
-catenin is known to participate in the Wnt signaling
pathway (30). In the presence of the APC mutation, degra-
dation of  -catenin diminished with accumulation of nucle-
ar  -catenin bound to transcriptional factors. As E-cadherin
competes with APC protein in binding to  -catenin, cytoplas-
mic concentration and nuclear shifting of  -catenin may be
influenced by both proteins (9). In our study, the membrane
expression of  -catenin was predominantly reduced, where-
as nuclear expression was prominent, in both SRCC and in
the control groups. Down-regulation of E-cadherin may affect
the decreased membrane expression and nuclear shifting of
-catenin, even though we could not find any correlation
between the membrane expression of E-cadherin and  -
catenin. Interestingly, colorectal SRCC showing nuclear
expression of  -catenin may also share common characteristics
with the ordinary colorectal tumorigenesis at an early stage.
In conclusion, the aggressive behavior of colorectal SRCC
appears to be closely related to the down-regulation of E-cad-
herin. However, the precise genetic and epigenetic changes
involved in SRCC remains to be verified in order to under-
stand the various phenotypic expression of E-cadherin.
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